Skip to main content

Table 4 Cox univariate and multivariate analysis for time to progression and overall survival

From: Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

Risk factor n Time to progression P Overall survival P
HR 95% CI HR 95% CI
Univariate analysis
RRM1
 Normal 211 1.00 Referent   1.00 Referent  
 Aberration 40 0.86 (0.57-1.29) 0.46    
 Aberration 0–1.5 years*      0.59 (0.34-1.03) 0.06
 Aberration 1.5-7.4 years*      1.67 (1.06-2.62) 0.03
RRM2B
 Normal 217 1.00 Referent   1.00 Referent  
 Aberration 34 1.45 (0.94-2.25) 0.09 1.13 (0.78-1.64) 0.52
2R
 Normal 184 1.00 Referent   1.00 Referent  
 Aberration 67 1.25 (0.92-1.69) 0.16    
 Aberration 0–1.5 years*      0.85 (0.56-1.28) 0.44
 Aberration 1.5-7.4 years*      1.44 (0.96-2.17) 0.08
Multivariate analysis a
RRM1 b
 Normal 211 1.00 Referent   1.00 Referent  
 Aberration 40 0.66 (0.43-1.03) 0.07    
 Aberration 0–1.5 years*      0.56 (0.32-0.99) 0.05
 Aberration 1.5-7.4 years*      1.72 (1.05-2.79) 0.03
RRM2B c
 Normal 217 1.00 Referent   1.00 Referent  
 Aberration 34 1.41 (0.88-2.23) 0.15 1.00 (0.68-1.47) 1.00
2R
 Normal 184 1.00 Referent   1.00 Referent  
 Aberration 67 0.92 (0.64-1.33) 0.66    
 Aberration 0–1.5 years*      0.80 (0.52-1.22) 0.30
 Aberration 1.5-7.4 years*      1.36 (0.89-2.09) 0.16
  1. Abbreviations: 2R aberration RRM1 and/or RRM2B aberrant, 2R normal RRM1 and RRM2B both normal, CI confidence interval, HR hazard ratio, RRM1 ribonucleotide reductase M1 subunit, RRM2B ribonucleotide reductase M2B subunit.
  2. aModels adjusted for the effects of PAM50 status, visceral disease, stage of disease, number of metastatic sites, and performance status. Models stratified for previous chemotherapy (none, n = 70; adjuvant, n = 86; locally advanced or metastatic, n = 95).
  3. bModel further adjusted for RRM2B.
  4. cModel further adjusted for RRM1.
  5. *Time-dependant variable. If nothing is mentioned the maximum follow-up is 7.4 years after randomization for OS and 6.0 years after randomization for TTP.